2

Docket No. USF-T156X Serial No. 10/073,065

## In the Claims

Claims 1-32 (Cancelled)

Claim 33 (Previously presented): An immunogenic composition comprising one or more plasmid DNA coacervated with chitosan, wherein said one or more plasmid DNA encode an M2 respiratory syncytial virus (RSV) antigen and at least three RSV antigens selected from the group consisting of F, G, M, SH, NS1, NS2, N, and P.

Claim 34 (Previously presented): The immunogenic composition of claim 33, wherein said one or more plasmid DNA encode said M2 RSV antigen, said F RSV antigen, said G RSV antigen, and at least one RSV antigen selected from the group consisting of M, SH, NS1, NS2, N, and P.

Claim 35 (Previously presented): The immunogenic composition of claim 33, wherein said one or more plasmid DNA encode each of said F, G, M, SH, NS1, NS2, N, and P RSV antigens.

Claim 36 (Previously presented): The immunogenic composition of claim 33, wherein said one or more plasmid DNA and said chitosan together form nanospheres.

Claim 37 (Previously presented): A method for raising an immune response in a host against RSV, comprising administering to the host an immunoeffective amount of the immunogenic composition of claim 33.

Claim 38 (Previously presented): The method of claim 37, wherein said administering is oral or intranasal.

J:\USI\T156X\Amend-Resp\SuppResp2.doc/DNB/mv

3

Docket No. USF-T156X Serial No. 10/073,065

Claim 39 (Previously presented): The method of claim 37, wherein said administering does not induce airway hyperreactivity.

Claim 40 (Previously presented): The method of claim 37, wherein the immunoeffective amount is administered in a single dose.

Claim 41 (Previously presented): The method of claim 37, wherein the immunoeffective amount is about 1 mg/kg host weight.

Claim 42 (Previously presented): The method of claim 37, wherein the one or more plasmid DNA encode the M2 RSV antigen, the F RSV antigen, the G RSV antigen, and at least one of the RSV antigens selected from the group consisting of M, SH, NS1, NS2, N, and P.

Claim 43 (Previously presented): The method of claim 37, wherein the one or more plasmid DNA encode each of the F, G, M, SH, NS1, NS2, N, and P RSV antigens.

Claim 44 (Previously presented): The method of claim 37, wherein the one or more plasmid DNA and the chitosan together form nanospheres.

Claim 45 (Previously presented): A method of making the immunogenic composition of claim 33, comprising cloning cDNA encoding the RSV antigens in one or more plasmids to form the one or more plasmid DNA; and coacervating said one or more plasmid DNA with the chitosan.

Claim 46 (Previously presented): The method of claim 45, wherein said coacervating results in the formation of nanospheres.

Claim 47 (Previously presented): The method of claim 45, wherein the one or more plasmid DNA encode the M2 RSV antigen, the F RSV antigen, the G RSV antigen, and at least one of the RSV antigens selected from the group consisting of M, SH, NS1, NS2, N, and P.

J:\USF\T156X\Amend-Resp\SuppResp2.doc/DNB/mv

4

Docket No. USF-T156X Serial No. 10/073,065

P. 06

Claim 48 (Previously presented): The method of claim 45, wherein the one or more plasmid DNA encode each of the F, G, M, SH, NS1, NS2, N, and P RSV antigens.

Claim 49 (Previously presented): The method of claim 45, wherein the one or more plasmids are pVAX plasmids.

Claim 50 (New): An immunogenic composition comprising one or more plasmid DNA coaccrvated with chitosan, wherein said one or more plasmid DNA encode an M2 respiratory syncytial virus (RSV) antigen, and at least three RSV antigens are selected from the group consisting of F, G, M, SH, NS1, NS2, N, and P, and wherein said immunogenic composition is an inhalant.

Claim 51 (New): The immunogenic composition of claim 50, wherein said one or more plasmid DNA encode said M2 RSV antigen, said F RSV antigen, said G RSV antigen, and at least one RSV antigen selected from the group consisting of M, SH, NS1, NS2, N, and P.

Claim 52 (New): The immunogenic composition of claim 50, wherein said one or more plasmid DNA encode each of said F, G, M, SH, NS1, NS2, N, and P RSV antigens.

Claim 53 (New): The immunogenic composition of claim 50, wherein said one or more plasmid DNA and said chitosan together form nanospheres.